Xenetic (XBIO) Biosciences announced the pricing of an underwritten offering of 735,000 shares of common stock at a price to the public of $6.12 per share, for gross proceeds of approximately $4.5M, before deducting underwriting discounts and commissions and other estimated offering expenses. All shares of common stock are being offered by Xenetic. The offering is expected to close on or about October 14, subject to the satisfaction of customary closing conditions. Canaccord Genuity is acting as the sole bookrunner for the offering.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XBIO:
